AUO Perioperative Use of Pembrolizumab plus Enfortumab Vedotin in Muscle-invasive Bladder Carcinoma

被引：0
|
作者：
Rexer, H. [1 ]
Merseburger, A. [2 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Deutsch Krebsgesell eV, Organgruppensprecher Arbeitsgemeinschaft Urol, Berlin, Germany
来源：
UROLOGIE | 2023年 / 62卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1262 / 1263
页数：2
相关论文
共 50 条
  • [1] Perioperative pembrolizumab or pembrolizumab plus Enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-905/EV-303
    Necchi, A.
    Bedke, J.
    Galsky, M. D.
    Shore, N. D.
    Xylinas, E.
    Jia, C.
    Dubrovsky, L.
    Homet, Moreno B.
    Witjes, A. J.
    EUROPEAN UROLOGY, 2023, 83 : S751 - S751
  • [2] Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
    Necchi, Andrea
    Bedke, Jens
    Galsky, Matt D.
    Shore, Neal D.
    Plimack, Elizabeth R.
    Xylinas, Evanguelos
    Jia, Calvin
    Hennika, Tammy
    Moreno, Blanca Homet
    Witjes, Alfred Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
    Necchi, Andrea
    Bedke, Jens
    Galsky, Matt D.
    Shore, Neal D.
    Xylinas, Evanguelos
    Jia, Calvin
    Dubrovsky, Leonid
    Moreno, Blanca Homet
    Witjes, J. Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Perioperative Usage of Pembrolizumab for Muscle-invasive Bladder Cancer
    Rexer, H.
    Bedke, J.
    Merseburger, A.
    UROLOGE, 2021, 60 (04): : 555 - 556
  • [5] KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
    Galsky, Matt D.
    Necchi, Andrea
    Shore, Neal D.
    Plimack, Elizabeth R.
    Jia, Calvin
    Sbar, Eric
    Moreno, Blanca Homet
    Witjes, Johannes Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] KEYNOTE-905/EV-303: A phase 3 study of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer
    Hennika, Tammy
    Galsky, Matthew D.
    Necchi, Andrea
    Shore, Neal D.
    Plimack, Elizabeth
    Jia, Calvin
    Moreno, Blanca Homet
    Witjes, J. Alfred
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 207 - 208
  • [7] Pembrolizumab plus enfortumab vedotin in urothelial cancer
    Santoni, Matteo
    Takeshita, Hideki
    Massari, Francesco
    Bamias, Aristotelis
    Cerbone, Linda
    Fiala, Ondrej
    Mollica, Veronica
    Buti, Sebastiano
    Santoni, Angela
    Bellmunt, Joaquim
    NATURE REVIEWS UROLOGY, 2024, 21 (07) : 387 - 388
  • [8] KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
    Hoimes, Christopher J.
    Bedke, Jens
    Loriot, Yohann
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh S.
    Moreno, Blanca Homet
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Perioperative Use of Pembrolizumab in muscle-invasive Bladder Cancer A randomized Phase 3 Trial evaluating Cystectomy combined with perioperative Administration of Pembrolizumab versus Cystectomy alone in Study Participants with muscle-invasive Bladder Cancer who are not eligible for Cisplatin Treatment (KEYNOTE-905) - AB 71/ 19 of AUO
    Rexer, H.
    Bedke, J.
    Merseburger, A.
    AKTUELLE UROLOGIE, 2020, 51 (05) : 418 - 420
  • [10] Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.
    Hoimes, Christopher J.
    Loriot, Yohann
    Bedke, Jens
    Nishiyama, Hiroyuki
    Kataria, Ritesh S.
    Moreno, Blanca Homet
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345